首页 > 最新文献

Monash Bioethics Review最新文献

英文 中文
A review of "Caregiving, Carebots, and Contagion". “护理、护理机器人和传染病”综述。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 Epub Date: 2022-08-06 DOI: 10.1007/s40592-022-00162-8
Wayne Shelton

How far can smart machines, or carebots, go in performing the profoundly intimate human work of patient caregivers? How will mechanization alter how we understand the essential features of the human task of caregiving and the role of the caregiver? It is these complex questions, with real world implications, that this article discusses in reviewing "Caregiving, Carebots, and Contagion" by philosopher and bioethicist Michael Brannagan.

智能机器或护理机器人能在多大程度上完成病人护理人员的亲密工作?机械化将如何改变我们对人类照料任务的基本特征和照料者角色的理解?这篇文章在回顾哲学家和生物伦理学家Michael Brannagan的《看护、看护机器人和传染病》时,讨论的正是这些具有现实世界含义的复杂问题。
{"title":"A review of \"Caregiving, Carebots, and Contagion\".","authors":"Wayne Shelton","doi":"10.1007/s40592-022-00162-8","DOIUrl":"https://doi.org/10.1007/s40592-022-00162-8","url":null,"abstract":"<p><p>How far can smart machines, or carebots, go in performing the profoundly intimate human work of patient caregivers? How will mechanization alter how we understand the essential features of the human task of caregiving and the role of the caregiver? It is these complex questions, with real world implications, that this article discusses in reviewing \"Caregiving, Carebots, and Contagion\" by philosopher and bioethicist Michael Brannagan.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40674253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Co-editors of the special issue "East European post-communist legacy in medicine, health care, and bioethics". 《东欧后共产主义医学、医疗保健和生物伦理学遗产》特刊的联合编辑。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 DOI: 10.1007/s40592-022-00173-5
Ana S Iltis, Nataliya Shok
{"title":"Co-editors of the special issue \"East European post-communist legacy in medicine, health care, and bioethics\".","authors":"Ana S Iltis,&nbsp;Nataliya Shok","doi":"10.1007/s40592-022-00173-5","DOIUrl":"10.1007/s40592-022-00173-5","url":null,"abstract":"","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10493684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bulgaria at the onset of clinical ethics consultation. 保加利亚开始进行临床伦理咨询。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 DOI: 10.1007/s40592-022-00158-4
Silviya Aleksandrova-Yankulovska

Background: Over the years, Bulgarian bioethics has been mainly an academic enterprise and fallen short of providing health professionals with skills for ethical decision-making. Clinical ethics support (CES) was piloted by the author through two bottom-up models - METAP (Modular, Ethical, Treatment, Allocation of resources, Process) and MCD (Moral Case Deliberation).

Aims: This paper aims to present and analyse developments in the area of clinical ethics and the first experiences in CES in Bulgaria.

Methodology: The project reported here included a review of relevant literature on CES methods and evaluation and a documentary review of data from two CES pilot projects: METAP and MCD.

Results: Most of the 69 METAP ethics meetings reviewed were first time meetings (88,4%); the average duration was 36 min and the average number of participants was four (44,9%). The meetings were organized in response to cases of severely or critically ill patients. The ethical dilemmas included choice of treatment (31,9%) and conflicts with the patient or their relatives (23,2%). Consensus was achieved in 34,8% of the cases. The situation was clarified with the patient (27,5%) and within the team (15,9%). The rights and obligations of both sides were discussed in 7,2% of the cases. The experience of the members of the Bulgarian Association of Bioethics and Clinical Ethics (BABCE) with MCD was also presented to justify the inference about the applicability of the two CES models in a Bulgarian context.

Conclusion: Among Eastern European countries Bulgaria has made progress in CES. Both METAP and MCD have been found to be useful methods.

背景:多年来,保加利亚生物伦理学主要是一项学术事业,未能为卫生专业人员提供伦理决策的技能。临床伦理支持(CES)由作者通过METAP(模块化、伦理、治疗、资源分配、过程)和MCD(道德案例审议)两个自下而上的模型进行试点。目的:本文旨在介绍和分析临床伦理学领域的发展和保加利亚CES的第一次经验。方法:这里报告的项目包括对CES方法和评价的相关文献的审查,以及对两个CES试点项目METAP和MCD的数据的文献审查。结果:69次METAP伦理会议中,绝大多数为首次会议(88.4%);平均持续时间为36分钟,平均参与者人数为4人(44.9%)。这些会议是针对重症或危重病人的病例而组织的。伦理困境包括治疗选择(31.9%)和与患者或其亲属的冲突(23.2%)。34.8%的病例达成共识。患者(27.5%)和团队(15.9%)明确了这一情况。在7.2%的案例中讨论了双方的权利和义务。还介绍了保加利亚生物伦理学和临床伦理学协会(BABCE)成员在MCD方面的经验,以证明两种CES模型在保加利亚情况下适用性的推断是合理的。结论:在东欧国家中,保加利亚在消费电子学方面取得了进步。METAP和MCD都是有用的方法。
{"title":"Bulgaria at the onset of clinical ethics consultation.","authors":"Silviya Aleksandrova-Yankulovska","doi":"10.1007/s40592-022-00158-4","DOIUrl":"https://doi.org/10.1007/s40592-022-00158-4","url":null,"abstract":"<p><strong>Background: </strong>Over the years, Bulgarian bioethics has been mainly an academic enterprise and fallen short of providing health professionals with skills for ethical decision-making. Clinical ethics support (CES) was piloted by the author through two bottom-up models - METAP (Modular, Ethical, Treatment, Allocation of resources, Process) and MCD (Moral Case Deliberation).</p><p><strong>Aims: </strong>This paper aims to present and analyse developments in the area of clinical ethics and the first experiences in CES in Bulgaria.</p><p><strong>Methodology: </strong>The project reported here included a review of relevant literature on CES methods and evaluation and a documentary review of data from two CES pilot projects: METAP and MCD.</p><p><strong>Results: </strong>Most of the 69 METAP ethics meetings reviewed were first time meetings (88,4%); the average duration was 36 min and the average number of participants was four (44,9%). The meetings were organized in response to cases of severely or critically ill patients. The ethical dilemmas included choice of treatment (31,9%) and conflicts with the patient or their relatives (23,2%). Consensus was achieved in 34,8% of the cases. The situation was clarified with the patient (27,5%) and within the team (15,9%). The rights and obligations of both sides were discussed in 7,2% of the cases. The experience of the members of the Bulgarian Association of Bioethics and Clinical Ethics (BABCE) with MCD was also presented to justify the inference about the applicability of the two CES models in a Bulgarian context.</p><p><strong>Conclusion: </strong>Among Eastern European countries Bulgaria has made progress in CES. Both METAP and MCD have been found to be useful methods.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10555214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of studies based on the use of questionnaires in the time of Covid-19 pandemic. Covid-19大流行期间基于问卷调查的研究评估。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 Epub Date: 2021-09-12 DOI: 10.1007/s40592-021-00136-2
Corinna Porteri

During the covid-19 pandemic a huge number of research projects have been promoted internationally, nationally and locally. This also happened in Italy which was the first affected European country. Among these studies, research protocols based on the use of online questionnaires to evaluate the reaction of health workers and researchers to the emergency situation and their state of well-being were promoted. This contribution focuses on research protocols based on the use of online questionnaires and presents as a case study three different research proposals with the purpose of showing their different degree of compliance to scientific and ethical requirements and the need for a clear regulation. A guideline for the assessment of studies based on questionnaires is then suggested, in the absence of a national regulation on the issue. Having established rules, albeit flexible, can help to guarantee transparency in the evaluation process and contribute to the scientific and ethical compliance of the research.

在2019冠状病毒病大流行期间,国际、国家和地方推动了大量研究项目。这也发生在意大利,这是第一个受影响的欧洲国家。在这些研究中,推广了基于使用在线问卷来评估卫生工作者和研究人员对紧急情况的反应及其福祉状况的研究方案。本贡献侧重于基于使用在线问卷的研究方案,并作为案例研究提出了三种不同的研究建议,目的是显示它们对科学和伦理要求的不同程度的遵守以及对明确监管的需求。在没有关于这个问题的国家条例的情况下,然后提出了一项评价基于调查表的研究的准则。建立规则,尽管是灵活的,可以帮助保证评估过程的透明度,并有助于研究的科学和道德合规。
{"title":"Assessment of studies based on the use of questionnaires in the time of Covid-19 pandemic.","authors":"Corinna Porteri","doi":"10.1007/s40592-021-00136-2","DOIUrl":"https://doi.org/10.1007/s40592-021-00136-2","url":null,"abstract":"<p><p>During the covid-19 pandemic a huge number of research projects have been promoted internationally, nationally and locally. This also happened in Italy which was the first affected European country. Among these studies, research protocols based on the use of online questionnaires to evaluate the reaction of health workers and researchers to the emergency situation and their state of well-being were promoted. This contribution focuses on research protocols based on the use of online questionnaires and presents as a case study three different research proposals with the purpose of showing their different degree of compliance to scientific and ethical requirements and the need for a clear regulation. A guideline for the assessment of studies based on questionnaires is then suggested, in the absence of a national regulation on the issue. Having established rules, albeit flexible, can help to guarantee transparency in the evaluation process and contribute to the scientific and ethical compliance of the research.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39407114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Intervention hesitancy among healthcare personnel: conceptualizing beyond vaccine hesitancy. 卫生保健人员干预犹豫:概念化超出疫苗犹豫
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 Epub Date: 2022-03-20 DOI: 10.1007/s40592-022-00152-w
Rachel Gur-Arie, Nadav Davidovitch, Anat Rosenthal

We propose an emerging conceptualization of "intervention hesitancy" to address a broad spectrum of hesitancy to disease prevention interventions among healthcare personnel (HCP) beyond vaccine hesitancy. To demonstrate this concept and its analytical benefits, we used a qualitative case-study methodology, identifying a "spectrum" of disease prevention interventions based on (1) the intervention's effectiveness, (2) how the intervention is regulated among HCP in the Israeli healthcare system, and (3) uptake among HCP in the Israeli healthcare system. Our cases ultimately contribute to a more nuanced conceptualization of hesitancy that HCP express towards disease prevention interventions. Our case interventions included the seasonal influenza vaccine, the Mantoux test, and the hepatitis B (HBV) vaccine. Influenza and HBV are vaccine-preventable diseases, though their respective vaccines vary significantly in effectiveness and uptake among HCP. The Mantoux test is a tuberculin skin test which provides a prevention benchmark for tuberculosis (TB), a non-vaccine preventable disease. We conducted semi-structured interviews with relevant stakeholders and analyzed them within Israeli and international policy context between 2016 and 2019, a period just prior to the COVID-19 pandemic. We propose the conceptualization of "intervention hesitancy"-beyond "vaccine hesitancy"-as "hesitancy towards a wide range of public health interventions, including but not limited to vaccines". Results suggested that intervention hesitancy among HCP is rooted in weak trust in their employer, poor employment conditions, as well as mixed institutional guidelines and culture. Conceptualizing intervention hesitancy expands the ability of healthcare systems to understand the root of hesitancy and foster a supportive institutional culture and trust, cognizant of diverse disease prevention interventions beyond vaccination.

我们提出了一个新兴的 "干预犹豫 "概念,以解决医疗保健人员(HCP)在疫苗犹豫之外对疾病预防干预措施的广泛犹豫。为了证明这一概念及其分析优势,我们采用了定性案例研究方法,根据以下几点确定了疾病预防干预措施的 "范围":(1)干预措施的有效性;(2)以色列医疗保健系统中如何规范医护人员的干预措施;以及(3)以色列医疗保健系统中医护人员对干预措施的接受程度。我们的案例最终有助于从更细微的概念上理解卫生保健人员对疾病预防干预措施的犹豫不决。我们的案例干预措施包括季节性流感疫苗、曼图氏试验和乙型肝炎 (HBV) 疫苗。流感和乙型肝炎 (HBV) 是可通过疫苗预防的疾病,但这两种疫苗的效果和在卫生保健人员中的使用率差别很大。Mantoux 试验是一种结核菌素皮肤试验,为结核病(TB)这种非疫苗可预防疾病提供了预防基准。我们对相关利益攸关方进行了半结构化访谈,并在 2016 年至 2019 年期间,即 COVID-19 大流行之前的以色列和国际政策背景下对访谈内容进行了分析。我们提出了 "干预犹豫 "的概念--除 "疫苗犹豫 "外,还包括 "对包括但不限于疫苗在内的各种公共卫生干预措施的犹豫"。研究结果表明,卫生保健人员对干预措施犹豫不决的根源在于对雇主的信任度低、就业条件差以及机构准则和文化参差不齐。将干预犹豫概念化可提高医疗保健系统的能力,使其了解犹豫的根源,培养支持性的机构文化和信任,认识到除疫苗接种以外的各种疾病预防干预措施。
{"title":"Intervention hesitancy among healthcare personnel: conceptualizing beyond vaccine hesitancy.","authors":"Rachel Gur-Arie, Nadav Davidovitch, Anat Rosenthal","doi":"10.1007/s40592-022-00152-w","DOIUrl":"10.1007/s40592-022-00152-w","url":null,"abstract":"<p><p>We propose an emerging conceptualization of \"intervention hesitancy\" to address a broad spectrum of hesitancy to disease prevention interventions among healthcare personnel (HCP) beyond vaccine hesitancy. To demonstrate this concept and its analytical benefits, we used a qualitative case-study methodology, identifying a \"spectrum\" of disease prevention interventions based on (1) the intervention's effectiveness, (2) how the intervention is regulated among HCP in the Israeli healthcare system, and (3) uptake among HCP in the Israeli healthcare system. Our cases ultimately contribute to a more nuanced conceptualization of hesitancy that HCP express towards disease prevention interventions. Our case interventions included the seasonal influenza vaccine, the Mantoux test, and the hepatitis B (HBV) vaccine. Influenza and HBV are vaccine-preventable diseases, though their respective vaccines vary significantly in effectiveness and uptake among HCP. The Mantoux test is a tuberculin skin test which provides a prevention benchmark for tuberculosis (TB), a non-vaccine preventable disease. We conducted semi-structured interviews with relevant stakeholders and analyzed them within Israeli and international policy context between 2016 and 2019, a period just prior to the COVID-19 pandemic. We propose the conceptualization of \"intervention hesitancy\"-beyond \"vaccine hesitancy\"-as \"hesitancy towards a wide range of public health interventions, including but not limited to vaccines\". Results suggested that intervention hesitancy among HCP is rooted in weak trust in their employer, poor employment conditions, as well as mixed institutional guidelines and culture. Conceptualizing intervention hesitancy expands the ability of healthcare systems to understand the root of hesitancy and foster a supportive institutional culture and trust, cognizant of diverse disease prevention interventions beyond vaccination.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47749958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dignity at the end of life: from philosophy to health care practice - Lithuanian case. 生命终结时的尊严:从哲学到保健实践——立陶宛案例。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 DOI: 10.1007/s40592-022-00160-w
Žydrūnė Luneckaitė, Olga Riklikienė

Regulation and clinical practices regarding end of human life care differ among the nations and countries. These differences reflect the history of the development of state health systems, different societal values, and different understandings of dignity and what it means to protect or respect dignity. The result is variation in the ethical, legal, and practical approaches to end-of-life issues. The article analyzes the diversity of strategies to strengthen dignity at the end of life of terminally ill patients and to highlight the legal preconditions and limitations for implementing these strategies in independent Lithuania, as a former state of the Soviet Union. It is based on the critical analysis of philosophical literature, legal national and international documents and scientific evidence related to the issue. The author argues that the legal system in Lithuania is not sufficient to ensure the patient's dignity at the end of life and remains far behind other Western European countries. Legal regulations in Lithuania do not guarantee the right of the patient to express his or her will regarding the future treatment, including the refusal of resuscitation, do not regulate the termination of burdensome, non-viable and meaningless treatment that is undesired by the patient, and limit the accessibility of palliative care with its necessary quality and comfort.

关于人类生命终结护理的法规和临床实践在不同的国家和地区有所不同。这些差异反映了国家卫生系统发展的历史、不同的社会价值观以及对尊严的不同理解以及保护或尊重尊严的含义。其结果是在伦理、法律和实际处理临终问题的方法上发生了变化。本文分析了加强绝症患者生命结束时尊严的战略的多样性,并强调了在独立的立陶宛实施这些战略的法律前提和限制,作为前苏联的一个国家。它基于对哲学文献、国内和国际法律文件以及与该问题相关的科学证据的批判性分析。提交人认为,立陶宛的法律制度不足以确保病人在生命结束时的尊严,远远落后于其他西欧国家。立陶宛的法律法规不保障患者表达其对未来治疗的意愿的权利,包括拒绝复苏,也不规范终止患者不希望的负担,不可行和无意义的治疗,并且限制了姑息治疗的必要质量和舒适性。
{"title":"Dignity at the end of life: from philosophy to health care practice - Lithuanian case.","authors":"Žydrūnė Luneckaitė,&nbsp;Olga Riklikienė","doi":"10.1007/s40592-022-00160-w","DOIUrl":"https://doi.org/10.1007/s40592-022-00160-w","url":null,"abstract":"<p><p>Regulation and clinical practices regarding end of human life care differ among the nations and countries. These differences reflect the history of the development of state health systems, different societal values, and different understandings of dignity and what it means to protect or respect dignity. The result is variation in the ethical, legal, and practical approaches to end-of-life issues. The article analyzes the diversity of strategies to strengthen dignity at the end of life of terminally ill patients and to highlight the legal preconditions and limitations for implementing these strategies in independent Lithuania, as a former state of the Soviet Union. It is based on the critical analysis of philosophical literature, legal national and international documents and scientific evidence related to the issue. The author argues that the legal system in Lithuania is not sufficient to ensure the patient's dignity at the end of life and remains far behind other Western European countries. Legal regulations in Lithuania do not guarantee the right of the patient to express his or her will regarding the future treatment, including the refusal of resuscitation, do not regulate the termination of burdensome, non-viable and meaningless treatment that is undesired by the patient, and limit the accessibility of palliative care with its necessary quality and comfort.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10498572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why catastrophic events, human enhancement and progress in robotics may limit individual health rights. 为什么灾难性事件、人类的增强和机器人技术的进步可能限制个人的健康权利。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 Epub Date: 2022-01-23 DOI: 10.1007/s40592-021-00150-4
Konrad Szocik

Despite the fact that people usually believe that individual health rights have an intrinsic value, they have, in fact, only extrinsic value. They are context dependent. While in normal conditions the current societies try to guarantee individual health rights, the challenge arises in emergency situations. Ones of them are pandemics including current covid-19 pandemic. Emergency situations challenge individual health rights due to insufficient medical resources and non-random criteria of selection of patients. However, there are some reasons to assume that societal and technological processes in the near future will threaten permanently individual health rights in normal conditions. Such processes include progress in commonly available human enhancement technologies, and progress in robotics and automation. In this paper I show how individual health rights will be challenged in both scenarios including catastrophic events and future technological progress. In both cases, the idea of assisted dying is discussed as possibly the unique healthcare principle available for people whose individual health rights will be limited or canceled due to catastrophes or technological and financial exclusion. The special case of future space missions is also discussed as an example of an extreme environment affecting the way moral norms are viewed in health care ethics.

尽管人们通常认为个人健康权具有内在价值,但实际上它们只有外在价值。它们依赖于上下文。虽然当前社会在正常情况下努力保障个人健康权,但在紧急情况下出现了挑战。其中之一是大流行,包括当前的covid-19大流行。由于医疗资源不足和选择病人的标准非随机,紧急情况对个人健康权构成挑战。然而,有一些理由认为,在不久的将来,社会和技术进程将永久威胁到正常条件下的个人健康权。这些过程包括普遍可用的人类增强技术的进步,以及机器人和自动化的进步。在本文中,我展示了个人健康权利将如何在两种情况下受到挑战,包括灾难性事件和未来的技术进步。在这两种情况下,辅助死亡的想法都被讨论为可能是个人健康权利因灾难或技术和经济排斥而受到限制或取消的人可用的独特保健原则。还讨论了未来空间任务的特殊情况,作为极端环境影响在保健伦理中看待道德规范方式的一个例子。
{"title":"Why catastrophic events, human enhancement and progress in robotics may limit individual health rights.","authors":"Konrad Szocik","doi":"10.1007/s40592-021-00150-4","DOIUrl":"https://doi.org/10.1007/s40592-021-00150-4","url":null,"abstract":"<p><p>Despite the fact that people usually believe that individual health rights have an intrinsic value, they have, in fact, only extrinsic value. They are context dependent. While in normal conditions the current societies try to guarantee individual health rights, the challenge arises in emergency situations. Ones of them are pandemics including current covid-19 pandemic. Emergency situations challenge individual health rights due to insufficient medical resources and non-random criteria of selection of patients. However, there are some reasons to assume that societal and technological processes in the near future will threaten permanently individual health rights in normal conditions. Such processes include progress in commonly available human enhancement technologies, and progress in robotics and automation. In this paper I show how individual health rights will be challenged in both scenarios including catastrophic events and future technological progress. In both cases, the idea of assisted dying is discussed as possibly the unique healthcare principle available for people whose individual health rights will be limited or canceled due to catastrophes or technological and financial exclusion. The special case of future space missions is also discussed as an example of an extreme environment affecting the way moral norms are viewed in health care ethics.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39939863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Russian orthodox church on bioethical debates: the case of ART. 俄罗斯东正教关于生命伦理的辩论:ART的案例。
IF 1.6 Q1 Arts and Humanities Pub Date : 2022-12-01 DOI: 10.1007/s40592-022-00154-8
Roman Tarabrin

This article assesses the role of an important Russian public institution, the Russian Orthodox Church (ROC), in shaping the religious discourse on bioethics in Russia. An important step in this process was the approval of 'The Basis of the Social Concept of the Russian Orthodox Church' (2000), one chapter of which is devoted to bioethics. However, certain inadequacies in the creation of this document resulted in the absence of a clear position of the Russian Orthodox Church on some end-of-life issues, reproductive technologies, embryo stem cells, and other topics.Using the example of reproductive dilemmas, the author researches how the ROC clarifies its teaching on issues relating to bioethics. In the 2010s the ROC introduced a new method of taking into account the views of believers and the articulation of the church's position. This article examines the extensive public discussion of a new document, 'Ethical issues Associated with In Vitro Fertilization'.

本文评估了一个重要的俄罗斯公共机构,俄罗斯东正教会(ROC),在塑造俄罗斯的生命伦理宗教话语的作用。这一过程中的一个重要步骤是批准了“俄罗斯东正教社会概念基础”(2000年),其中一章专门讨论了生命伦理学。然而,在这份文件的创建过程中,某些不足之处导致俄罗斯东正教会在一些生命终结问题、生殖技术、胚胎干细胞和其他主题上缺乏明确的立场。以生殖困境为例,探讨中华民国如何澄清其生命伦理问题的教学。在2010年代,中华民国引入了一种新的方法来考虑信徒的观点和教会立场的表达。本文探讨了一份新文件的广泛公开讨论,“与体外受精相关的伦理问题”。
{"title":"Russian orthodox church on bioethical debates: the case of ART.","authors":"Roman Tarabrin","doi":"10.1007/s40592-022-00154-8","DOIUrl":"https://doi.org/10.1007/s40592-022-00154-8","url":null,"abstract":"<p><p>This article assesses the role of an important Russian public institution, the Russian Orthodox Church (ROC), in shaping the religious discourse on bioethics in Russia. An important step in this process was the approval of 'The Basis of the Social Concept of the Russian Orthodox Church' (2000), one chapter of which is devoted to bioethics. However, certain inadequacies in the creation of this document resulted in the absence of a clear position of the Russian Orthodox Church on some end-of-life issues, reproductive technologies, embryo stem cells, and other topics.Using the example of reproductive dilemmas, the author researches how the ROC clarifies its teaching on issues relating to bioethics. In the 2010s the ROC introduced a new method of taking into account the views of believers and the articulation of the church's position. This article examines the extensive public discussion of a new document, 'Ethical issues Associated with In Vitro Fertilization'.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context. 新冠肺炎人类挑战研究中的风险、收益和社会价值:历史背景下的大流行决策
IF 1.6 Q2 ETHICS Pub Date : 2022-12-01 Epub Date: 2022-06-15 DOI: 10.1007/s40592-022-00156-6
Mabel Rosenheck

During the Covid-19 pandemic, ethicists and researchers proposed human challenge studies as a way to speed development of a vaccine that could prevent disease and end the global public health crisis. The risks to healthy volunteers of being deliberately infected with a deadly and novel pathogen were not low, but the benefits could have been immense. This essay is a history of the three major efforts to set up a challenge model and run challenge studies in 2020 and 2021. The pharmaceutical company Johnson and Johnson, the National Institutes of Health in the United States, and a private-public partnership of industry, university, and government partners in Britain all undertook preparations. The United Kingdom's consortium began their Human Challenge Programme in March of 2021.Beyond documenting each effort, the essay puts these scientific and ethical debates in dialogue with the social, epidemiological, and institutional conditions of the pandemic as well as the commercial, intellectual, and political systems in which medical research and Covid-19 challenge studies operated. It shows how different institutions understood risk, benefit, and social value depending on their specific contexts. Ultimately the example of Covid-19 challenge studies highlights the constructedness of such assessments and reveals the utility of deconstructing them retrospectively so as to better understand the interplay of medical research and research ethics with larger social systems and historical contexts.

在 Covid-19 大流行期间,伦理学家和研究人员提议进行人体挑战研究,以此加快疫苗的研发,从而预防疾病,结束全球公共卫生危机。蓄意感染一种致命的新型病原体对健康志愿者造成的风险并不低,但带来的益处却可能是巨大的。本文记录了为建立挑战模型并在 2020 年和 2021 年开展挑战研究而做出的三大努力。强生制药公司、美国国立卫生研究院和英国的一个由企业、大学和政府合作伙伴组成的公私合作组织都进行了准备工作。除了记录每项工作外,这篇文章还将这些科学和伦理辩论与大流行病的社会、流行病学和机构条件以及医学研究和 Covid-19 挑战研究运作的商业、知识和政治体系进行了对话。它展示了不同机构如何根据其具体情况理解风险、利益和社会价值。最终,Covid-19 挑战研究的例子凸显了此类评估的建构性,并揭示了回溯解构此类评估的效用,从而更好地理解医学研究和研究伦理与更大的社会体系和历史背景之间的相互作用。
{"title":"Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context.","authors":"Mabel Rosenheck","doi":"10.1007/s40592-022-00156-6","DOIUrl":"10.1007/s40592-022-00156-6","url":null,"abstract":"<p><p>During the Covid-19 pandemic, ethicists and researchers proposed human challenge studies as a way to speed development of a vaccine that could prevent disease and end the global public health crisis. The risks to healthy volunteers of being deliberately infected with a deadly and novel pathogen were not low, but the benefits could have been immense. This essay is a history of the three major efforts to set up a challenge model and run challenge studies in 2020 and 2021. The pharmaceutical company Johnson and Johnson, the National Institutes of Health in the United States, and a private-public partnership of industry, university, and government partners in Britain all undertook preparations. The United Kingdom's consortium began their Human Challenge Programme in March of 2021.Beyond documenting each effort, the essay puts these scientific and ethical debates in dialogue with the social, epidemiological, and institutional conditions of the pandemic as well as the commercial, intellectual, and political systems in which medical research and Covid-19 challenge studies operated. It shows how different institutions understood risk, benefit, and social value depending on their specific contexts. Ultimately the example of Covid-19 challenge studies highlights the constructedness of such assessments and reveals the utility of deconstructing them retrospectively so as to better understand the interplay of medical research and research ethics with larger social systems and historical contexts.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41937447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The creation of the Belmont Report and its effect on ethical principles: a historical study. 贝尔蒙特报告》的创作及其对伦理原则的影响:一项历史研究。
IF 1.6 Q2 ETHICS Pub Date : 2022-12-01 Epub Date: 2022-11-10 DOI: 10.1007/s40592-022-00165-5
Hiroyuki Nagai, Eisuke Nakazawa, Akira Akabayashi

The Belmont Report continues to be held in high regard, and most bioethical analyses conducted in recent years have presumed that it affects United States federal regulations. However, the assessments of the report's creators are sharply divided. Understanding the historic reputation of this monumental report is thus crucial. We first recount the historical context surrounding the creation of this report. Subsequently, we review the process involved in developing ethical guidelines and describe the report's features. Additionally, we analyze the effect of unfolding events on the subsequent creation of federal regulations, especially on gene therapy clinical trials. Moreover, throughout this paper we evaluate the ethical principles outlined in this report and describe how they overlap with the issue of protecting socially vulnerable groups. Based on the analysis, we conclude that the features of the Belmont Report cannot be considered as having affected the basic sections of the federal regulations for ethical reviews that were made uniform in 1981. Nevertheless, regarding the regulations on gene therapy clinical trials-which were at first expected to be applicable to research involving children-in addition to implementing policies regarding the public review of protocols that passed ethical review, this report's principles are clearly reflected in the key notes that should have been referred to when the report was created.

贝尔蒙特报告》继续受到高度评价,近年来进行的大多数生物伦理分析都假定该报 告影响了美国联邦法规。然而,对该报告创作者的评价却众说纷纭。因此,了解这份不朽报告的历史声誉至关重要。我们首先回顾了该报告产生的历史背景。随后,我们回顾了制定伦理指南的过程,并介绍了报告的特点。此外,我们还分析了事件发展对随后制定联邦法规的影响,尤其是对基因治疗临床试验的影响。此外,在本文中,我们还对报告中概述的伦理原则进行了评估,并阐述了这些原则与保护社会弱势群体问题的重叠之处。根据分析,我们得出结论,《贝尔蒙特报告》的特点不能被视为影响了 1981 年统一制定的联邦伦理审查法规的基本部分。尽管如此,关于基因治疗临床试验的规定--起初预计将适用于涉及儿童的研究--除了实施有关对通过伦理审查的方案进行公开审查的政策外,该报告的原则在关键说明中得到了明确的体现,而这些关键说明本应在该报告制定时得到参考。
{"title":"The creation of the Belmont Report and its effect on ethical principles: a historical study.","authors":"Hiroyuki Nagai, Eisuke Nakazawa, Akira Akabayashi","doi":"10.1007/s40592-022-00165-5","DOIUrl":"10.1007/s40592-022-00165-5","url":null,"abstract":"<p><p>The Belmont Report continues to be held in high regard, and most bioethical analyses conducted in recent years have presumed that it affects United States federal regulations. However, the assessments of the report's creators are sharply divided. Understanding the historic reputation of this monumental report is thus crucial. We first recount the historical context surrounding the creation of this report. Subsequently, we review the process involved in developing ethical guidelines and describe the report's features. Additionally, we analyze the effect of unfolding events on the subsequent creation of federal regulations, especially on gene therapy clinical trials. Moreover, throughout this paper we evaluate the ethical principles outlined in this report and describe how they overlap with the issue of protecting socially vulnerable groups. Based on the analysis, we conclude that the features of the Belmont Report cannot be considered as having affected the basic sections of the federal regulations for ethical reviews that were made uniform in 1981. Nevertheless, regarding the regulations on gene therapy clinical trials-which were at first expected to be applicable to research involving children-in addition to implementing policies regarding the public review of protocols that passed ethical review, this report's principles are clearly reflected in the key notes that should have been referred to when the report was created.</p>","PeriodicalId":43628,"journal":{"name":"Monash Bioethics Review","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40456189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Monash Bioethics Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1